Laboratory receiveS R01 funding from NIAID to support next-generation malaria vaccine effortS11/29/2018
The Murphy Laboratory has received funding from the U.S. National Institute for Allergy and Infectious Diseases (NIAID) of the National Institutes of Health to support further development of the prime-and-trap malaria vaccine published earlier this year. The five-year, $3.86M award will support basic and translational immunology studies by our Laboratory and our collaborators at the NIH Vaccine Research Center, Seattle Children's Research Center, Sanaria, and the Washington National Primate Research Center. Dr. Murphy serves as the award's Principal Investigator. A special thanks to Tayla, Zach, and Brad who laid the initial groundwork for these efforts in our laboratory and to Bill Heath's Laboratory in Melbourne for pointing the malaria field in the direction of liver resident memory T cells in early 2016. For more information, go to our Research page or contact the Laboratory.
Comments are closed.
|
Lab PostUpdates about lab activities, papers and other insights! Archives
April 2024
Categories |